NATURAL HOLISTIC MEDICINE BLOG - When Lisa Rees began her treatment with a weight loss medication this past April, her primary goal was to shed a few kilograms. However, she soon discovered an unintended and transformative side effect: a drastic reduction in her desire to consume alcohol.
Like many others now taking medications such as Wegovy, Mounjaro, and Ozempic, Lisa found that her relationship with drinking changed almost overnight.
This shift has prompted a growing number of patients and medical professionals to investigate the potential link between GLP-1 receptor agonists and decreased substance cravings.
Patient Experiences: A Shift in Consumption Habits
Lisa, a 46-year-old from South Wales, UK, recounts how she used to consume two bottles of wine during a typical night out with friends.
Since starting her medication, she finds that after just a couple of glasses, she is physically unable to drink another drop.
This sentiment is echoed by Warren Thomas, a 45-year-old from Colchester, who noticed a significant change within just 24 hours of his first dose in mid-June.
Warren reports that his alcohol tolerance has effectively dropped to zero, leaving him feeling dizzy after only two beers.
Conversely, the impact is not universally welcomed by everyone navigating these treatments.
Faye Goodwin, a 20-year-old recent graduate, has struggled with the social implications of this side effect, noting that nausea and acid reflux often make social drinking difficult or impossible.
The Science Behind the GLP-1 Effect
These popular weight loss medications function by mimicking a natural hormone called GLP-1, which regulates appetite and keeps patients feeling full for longer periods.
Emerging research, however, suggests these drugs may also influence the brain's reward system, potentially dampening cravings for substances like alcohol and nicotine.
Dr.
Christian Hendershot, based at the University of Southern California, has been instrumental in this field of study.
In 2025, he published a small-scale study where participants with alcohol use disorder reported fewer urges to drink while using Ozempic.
Further supporting this, a recent study from the University of Colorado Anschutz indicated that GLP-1 medications in pill form successfully reduced the number of heavy drinking days in patients.
This suggests that the impact on reward pathways in the brain could be a crucial mechanism for future treatments.
Medical Guidance and Potential Risks
While the reduction in alcohol intake may seem like a benefit for those trying to lose weight, medical experts emphasize caution.
According to Professor Russell Hearn, a GP and Professor of Medicine at King's College London, there are currently no formal recommendations regarding alcohol consumption while on these weight loss injections.
The NHS advises that individuals should not consume more than 14 units of alcohol per week to avoid long-term health complications such as hypertension and liver damage.
Physicians like Dr.
Hearn remind patients that while drinking less may assist in weight loss, the primary focus remains on dietary changes and medical safety.
Furthermore, experts like Dr.
Darren Quelch, an addiction researcher at the University of South Wales, highlight that more research is needed to determine the long-term safety of using these drugs for addiction treatment.
Rare but serious side effects, such as pancreatitis, mean that patients must be carefully monitored by their healthcare providers.
The Future of Addiction Treatment
The medical community is now looking beyond weight loss to see if GLP-1 drugs could serve as viable treatments for other addictions, including smoking and opioids.
However, Dr.
Joseph Schacht cautions that larger, long-term clinical trials are necessary before regulators can formally approve these drugs for such indications.
For patients like Warren Thomas, the unexpected sobriety has been a welcome change, even if he never initially considered his drinking a problem.
As data continues to accumulate, the medical world remains hopeful that these medications could provide a dual benefit for both physical health and addictive behaviors.
Frequently Asked Questions (FAQ)
Do Wegovy, Mounjaro, and Ozempic officially treat alcohol addiction?
Currently, these medications are not officially approved for the treatment of alcohol addiction.
While early studies show promise in reducing cravings, larger clinical trials are required before they can be prescribed for this purpose.
Why do these medications affect alcohol cravings?
These drugs mimic the GLP-1 hormone, which affects the reward system in the brain.
Researchers believe this interaction may reduce the desire for addictive substances like alcohol and nicotine by altering how the brain processes rewards.
Are there risks to drinking alcohol while on these medications?
Yes, patients report side effects like increased nausea, acid reflux, or lower alcohol tolerance.
Additionally, there are serious potential side effects of the medication itself, such as pancreatitis, which patients should monitor closely under medical supervision.
Should I consult my doctor if I notice changes in my drinking habits?
Absolutely.
It is essential to discuss any changes in appetite, alcohol consumption, or side effects with your healthcare provider to ensure your treatment plan remains safe and effective for your specific health needs.
Comments